Iodine-131, a beta- and gamma-emitting radioisotope with an 8-day half-life, remains one of the most versatile radionuclides for both diagnostic imaging and targeted radionuclide therapy in modern nuclear medicine. At Protheragen, our specialized I-131 radiolabeling platform empowers researchers and biopharma partners to advance radiopharmaceutical pipelines—from early discovery through preclinical validation and into IIT clinical investigations—with precision chemistry and rigorous quality oversight.
Radioiodination with iodine-131 involves the incorporation of this high-energy beta emitter into biologically active molecules—ranging from small-molecule ligands and peptides to monoclonal antibodies and antibody fragments—through either direct electrophilic substitution or indirect prosthetic-group conjugation. The direct approach typically targets electron-rich aromatic residues such as tyrosine or histidine, utilizing oxidizing agents like chloramine-T or the milder iodogen method to convert iodide (I-) into electrophilic iodine (I+) capable of regioselective attachment. For molecules lacking suitable iodination sites or those sensitive to oxidative conditions, indirect strategies employ pre-labeled prosthetic groups—such as Bolton–Hunter reagents, N-succinimidyl iodo-benzoate derivatives, or stannylated precursors for iododestannylation—that preserve the native pharmacological properties of the targeting vector while enabling stable iodine incorporation.
Fig 1. 131I-WBS and SPECT/CT of the neck obtained 3 days after administration of 3.7 GBq (100 mCi) 131I in order to ablate thyroid remnants in a patient who 2 months previously had undergone complete thyroidectomy because of DTC (pT3N0M0 with vascular invasion). (Szumowski, Piotr, et al., 2021)
The physical decay properties of I-131 make it uniquely valuable across the radiopharmaceutical landscape: its 606 keV beta emissions deliver therapeutic cytotoxicity for targeted radionuclide therapy, while accompanying 364 keV gamma emissions permit SPECT-based biodistribution imaging and dosimetry calculations. These dual capabilities position I-131 as a cornerstone isotope in theranostic development, where the same radiolabeled construct can first delineate tumor targeting specificity in vivo and subsequently deliver a calculated absorbed dose to malignant tissue. However, the chemistry demands meticulous optimization—reaction pH, temperature, stoichiometry, and purification strategy must be tightly controlled to achieve radiochemical purity exceeding 95%, minimize free iodide contamination, and ensure metabolic stability during systemic circulation.
Protheragen operates as a fully integrated Radiopharmaceutical CRDMO and CRO, bridging the translational gap from benchtop radiochemistry to clinical administration. Our I-131 radiolabeling service is architected around three core pillars: scientific rigor, regulatory foresight, and operational agility. Whether your program requires carrier-free I-131 labeling of a novel peptide ligand for receptor occupancy studies, conjugation of a tumor-targeting antibody for radioimmunotherapy evaluation, or GMP-compliant batch production to supply an IIT clinical trial, our multidisciplinary team—spanning radiochemists, analytical scientists, quality assurance specialists, and regulatory strategists—delivers end-to-end solutions tailored to your molecule's unique physicochemical and biological profile. We maintain active collaborations with isotope suppliers and certified nuclear pharmacies to ensure seamless procurement, handling, and dispatch of I-131 labeled products under full chain-of-custody documentation.
We execute chloramine-T, iodogen, and lactoperoxidase-mediated iodination protocols optimized for tyrosine- or histidine-containing peptides, proteins, and antibodies. Reaction conditions—including oxidant concentration, pH, temperature, and reaction time—are systematically screened to maximize radiochemical yield while preserving immunoreactivity and structural integrity.
For molecules lacking native iodination sites or susceptible to oxidative damage, we design and deploy prosthetic-group strategies including Bolton–Hunter acylation, SGMIB (N-succinimidyl 4-guanidinomethyl-3-iodobenzoate) conjugation, and maleimide-thiol chemistry. These approaches enable stable iodine attachment with minimal perturbation of receptor-binding affinity.
Our chemists specialize in metal-mediated halogen exchange reactions using aryltrialkylstannane or arylsilane precursors, achieving site-specific I-131 incorporation under mild conditions. This method is particularly advantageous for small molecules and modified peptides where regioselectivity and high molar activity are paramount.
Novel targeting vectors—whether small-molecule kinase inhibitors, peptides, single-domain antibodies, or antibody-drug conjugates—undergo feasibility assessment, precursor synthesis, labeling optimization, and purification method development. We provide comprehensive reaction parameter mapping and scale-up validation from microcurie to multicurie batches.
Every I-131 labeled batch is subjected to rigorous analytical characterization: thin-layer chromatography (TLC), high-performance liquid chromatography (HPLC), size-exclusion chromatography (SEC), and gamma spectrometry for radionuclidic identity. We additionally perform stability testing in physiologically relevant media (human serum, PBS, formulation buffer) to confirm resistance to deiodination over clinically relevant timeframes.
Beyond radiolabeling, we offer integrated preclinical evaluation packages encompassing in vitro cell binding assays, internalization kinetics, cytotoxicity studies, and in vivo biodistribution studies in rodent tumor models. SPECT/CT imaging capabilities enable real-time visualization of tumor targeting, pharmacokinetic profiling, and dosimetry calculations to inform clinical translation strategy.
Our I-131 radiolabeling workflow is designed to be transparent, collaborative, and milestone-driven, ensuring that each project progresses from initial consultation to final product delivery with defined quality gates and regular scientific communication. The process is adaptable to both exploratory research objectives and regulated clinical manufacturing requirements.
Step 1: Project Consultation & Feasibility Assessment
Our radiochemistry team reviews your target molecule's structure, amino acid composition, and reported sensitivity to oxidation or pH extremes. We evaluate whether direct iodination, prosthetic-group conjugation, or halogen-exchange chemistry represents the optimal labeling strategy, and provide a detailed technical proposal including projected radiochemical yield, purity targets, and timeline.
Step 2: Precursor Synthesis & Characterization
For indirect labeling approaches, we synthesize and fully characterize the required precursor—whether a stannylated small molecule, a bifunctional chelator, or an activated ester prosthetic group—using NMR, LC-MS, and HPLC to confirm identity and purity before introducing radioactivity.
Step 3: Radiolabeling Reaction Optimization
We conduct small-scale labeling trials to optimize reaction parameters (pH, temperature, oxidant concentration, precursor-to-isotope ratio, and reaction time). Radiochemical yield and purity are monitored in real time via TLC and analytical HPLC, with conditions iteratively refined to achieve >95% radiochemical purity and minimal free iodide.
Step 4: Purification & Formulation
Labeled products are purified using solid-phase extraction (SPE), semi-preparative HPLC, or size-exclusion chromatography as appropriate, followed by sterile filtration and formulation in a clinically compatible buffer. Residual oxidants are neutralized with sodium metabisulfite or sodium thiosulfate quenching agents.
Step 5: Comprehensive Quality Control
Each batch undergoes multi-parameter QC testing: radiochemical purity (TLC/HPLC), radionuclidic purity (gamma spectrometry), pH, osmolality, sterility, endotoxin level (LAL test), and visual inspection. Stability samples are retained for longitudinal assessment.
Step 6: Preclinical Validation (Optional)
Upon request, we perform in vitro binding assays and in vivo biodistribution studies to confirm retention of biological activity, tumor-targeting specificity, and favorable pharmacokinetic profile—generating data packages that support IND-enabling toxicology and dosimetry studies.
Ready to advance your I-131 radiolabeling program from concept to clinic? Reach out to our scientific team today to discuss your molecule, timeline, and regulatory objectives. Whether you need a rapid feasibility assessment or a comprehensive manufacturing and clinical supply partnership, Protheragen is prepared to deliver precision radiochemistry tailored to your vision. Contact us now to schedule a confidential consultation and receive a customized service proposal.
Reference